Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of OK-1 in Advanced or Recurrent Solid Tumors
NCT04928508Phase 1Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Jul 2022
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OK1 in solid tumor, sponsored by University of Oklahoma. Primary endpoints: Number of dose-limiting toxicities at 21 days and Dosage Recommendation for Phase 2 at 21 days. Started Jul 2022; status: active, not recruiting.
02
Drugs
OK1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04928508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928508.